Infinity Pharma Shows Encouraging Eganelisib/Nivolumab Combo Data In Urothelial Cancer Study


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Infinity Pharmaceuticals Inc (NASDAQ: INFI) has announced a data presentation from MARIO-275 Phase 2 study evaluating eganelisib combined with Bristol-Myers Squibb's Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer at the 2021 ASCO Genitourinary Cancers Symposium.
  • In the overall population, the combination of eganelisib with nivolumab demonstrated an increase over nivolumab monotherapy in overall response rate (30% vs. 25%); disease control rate (55% vs. 31%); best responses of complete response (12% vs. 6%); stable disease (24% vs. 6%).
  • Data also showed that the addition of eganelisib on top of 2L standard of care nivolumab was well-tolerated and led to clear benefits for PD-L1 low patients, with an over 85% increase in ORR vs. the control arm. 
  • PD-L1 negative patients demonstrated an extended progression-free survival, reflecting a 46% reduction in the probability of progression of 9.1 weeks on the combination arm versus 7.9 weeks on the control arm.
  • Increased immune activation and decreased immune suppression were observed in combination therapy compared to monotherapy across PD-L1 negative and positive patients.
  • Registration-enabling study in PD-L1 low metastatic urothelial cancer is planned next.
  • Price Action: INFI stock increased 20% at $4.74 in premarket trading on the last check Thursday. 

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksFDAGeneralUrothelial Cancer